Takeuchi Taro, Zha Ling, Tanaka Kenta, Katayama Yusuke, Sobue Tomotaka, Hirayama Atsushi, Komukai Sho, Shimazu Takeshi, Kitamura Tetsuhisa
Environmental Medicine and Population Sciences, Department of Social Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
Traumatology and Acute Critical Medicine, Department of Acute Critical Medicine, Graduate School of Medicine, Osaka University, Suita, Japan.
IJID Reg. 2022 Jun;3:183-188. doi: 10.1016/j.ijregi.2022.04.001. Epub 2022 Apr 8.
To elucidate the clinical epidemiology and outcomes of patients with COVID-19 who received extracorporeal membrane oxygenation (ECMO) in the Osaka Prefecture, Japan.
We conducted a retrospective study of COVID-19 patients who received ECMO. Among patients diagnosed with COVID-19 between January 29 and November 9, 2020, we targeted patients who received ECMO. The outcome was all-cause mortality. The baseline characteristics of the COVID-19 patients who received ECMO were summarized according to the outcome. A univariable logistic regression model was applied to evaluate the association of each factor (sex, age group, city of residence, presence of comorbidities, presence of close contact, use of dialysis, and wave) with all-cause mortality. Odds ratios (ORs) with 95% confidence intervals were calculated.
Among the 14,864 patients diagnosed with COVID-19 during the study period, 39 patients received ECMO. Fourteen patients (35.9%) died. All patients aged 30-39 years survived, whereas all patients aged ≥80 years died. Higher mortality was observed among patients in the higher age group, and the value for trend was significant ( value for trend: 0.04).
Of the 14,864 COVID-19 patients in Osaka Prefecture until November 2020, 39 underwent ECMO. Of these, 14 died.
阐明在日本大阪府接受体外膜肺氧合（ECMO）治疗的新型冠状病毒肺炎（COVID-19）患者的临床流行病学及预后情况。
我们对接受ECMO治疗的COVID-19患者进行了一项回顾性研究。在2020年1月29日至11月9日期间被诊断为COVID-19的患者中，我们选取了接受ECMO治疗的患者。观察指标为全因死亡率。根据预后情况总结接受ECMO治疗的COVID-19患者的基线特征。应用单变量逻辑回归模型评估各因素（性别、年龄组、居住城市、合并症的存在、密切接触史的存在、透析的使用情况及疫情波次）与全因死亡率之间的关联。计算比值比（OR）及95%置信区间。
在研究期间确诊的14864例COVID-19患者中，39例接受了ECMO治疗。14例患者（35.9%）死亡。所有30 - 39岁的患者均存活，而所有年龄≥80岁的患者均死亡。在年龄较大的患者组中观察到较高的死亡率，且趋势检验P值具有统计学意义（趋势检验P值：0.04）。
截至2020年11月，大阪府14864例COVID-19患者中，39例接受了ECMO治疗。其中，14例死亡。
